Literature DB >> 7608255

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.

J C Crave1, S Fimbel, H Lejeune, N Cugnardey, H Déchaud, M Pugeat.   

Abstract

Evidence suggests that hyperinsulinemic insulin resistance may increase serum levels of ovarian androgens and reduce sex hormone-binding globulin (SHBG) levels in humans. The present study was conducted to assess the effect of administration of the biguanide metformin, a drug commonly used in the treatment of diabetes mellitus, on androgen and insulin levels in 24 hirsute patients. The patients selected for the study were obese, with a body mass index higher than 25 kg/m2 and high fasting insulin (> 90 pmol/L) and low SHBG levels (< 30 nmol/L). All patients were given a low calorie diet (1500 Cal/day) and randomized for either metformin administration at a dose of 850 mg or a placebo, twice daily for 4 months, in a double blind study. In the placebo group, diet resulted in a significant decrease in body mass index (30.8 +/- 1.0 vs. 32.7 +/- 1.5 kg/m2; P < 0.0001), fasting insulin (127 +/- 11 vs. 156 +/- 14 pmol/L; P < 0.01), non-SHBG-bound testosterone (0.19 +/- 0.02 vs. 0.28 +/- 0.03 nmol/L; P < 0.02), androstenedione (5.8 +/- 0.5 vs. 9.0 +/- 1.1 nmol/L; P < 0.03), and 3 alpha-diolglucuronide (8.6 +/- 1.1 vs. 11.7 +/- 1.9; P < 0.005) plasma concentrations and a significant increase in the glucose/insulin ratio (0.047 +/- 0.005 vs. 0.035 +/- 0.003; P < 0.001) and plasma concentrations of SHBG (26.0 +/- 3.3 vs. 19.1 +/- 1.9 nmol/L; P < 0.001) and dehydroepiandrosterone sulfate (8.7 +/- 1.5 vs. 8.4 +/- 1.3; P < 0.05). Beneficial effects of diet were not significantly different in the patients who were given metformin instead of placebo. These results confirm that weight loss induced by a low calorie diet is effective in improving hyperinsulinemia and hyperandrogenism in obese and hirsute women. With our study design, metformin administration had no additional benefit over the effect of diet.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608255     DOI: 10.1210/jcem.80.7.7608255

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Dehydroepiandrosterone sulfate levels in women. Relationships with age, body mass index and insulin levels.

Authors:  E Mazza; M Maccario; J Ramunni; C Gauna; A Bertagna; A M Barberis; S Patroncini; M Messina; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 2.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

Review 3.  Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology.

Authors:  Z E Hopkinson; N Sattar; R Fleming; I A Greer
Journal:  BMJ       Date:  1998-08-01

Review 4.  Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options?

Authors:  D A Ehrmann
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 5.  How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome?

Authors:  C Cortet-Rudelli; D Dewailly
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 6.  Insulin resistance, polycystic ovary syndrome and metformin.

Authors:  M Pugeat; P H Ducluzeau
Journal:  Drugs       Date:  1999       Impact factor: 9.546

7.  Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome.

Authors:  Esra Tasali; Florian Chapotot; Rachel Leproult; Harry Whitmore; David A Ehrmann
Journal:  J Clin Endocrinol Metab       Date:  2010-12-01       Impact factor: 5.958

Review 8.  Nutrition, hormones, and breast cancer: is insulin the missing link?

Authors:  R Kaaks
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

9.  The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.

Authors:  M Yilmaz; A Biri; A Karakoç; F Törüner; B Bingöl; N Cakir; B Tiras; G Ayvaz; M Arslan
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

Review 10.  Treatment of PCOS with metformin and other insulin-sensitizing agents.

Authors:  Emre Seli; Antoni J Duleba
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.